World news – Precigen (NASDAQ: PGEN) is now covered by Wells Fargo & Company


Log in to MarketBeat All Access to get access to all of MarketBeat’s research:

The Wells Fargo & Company, in a research note published Monday, broke coverage of Precigen (NASDAQ: PGEN), reports The Fly. The company has given the biotech company’s stock an « overweight » rating.

Other analysts recently released reports on the company. Zacks Investment Research downgraded Precigen from a « Hold » rating to a « Sell » rating in a research note on Tuesday, October 27th. HC Wainwright raised its price target for Precigen from USD 8.00 to USD 10.00 and gave the company a « Buy » research note on Wednesday, December 16. Finally, B. Riley initiated coverage of Precigen in a report on Wednesday, February 17th. They set a Buy recommendation and a price target of USD 10.00 for the company. One investment analyst has rated the stock as sell and four have given the stock a buy rating. The company currently has an average rating of « Buy » and a consensus price target of $ 9.56.

Precigen stock opened at $ 7.81 on Monday. The company has a leverage ratio of 3.31, a current of 4.93 and a fast of 4.59. Precigen has a 1-year low of $ 1.26 and a 1-year high of $ 11.10. The company has a market cap of $ 1.45 billion, a PE ratio of -4.15, and a beta of 2.31. The 50-day moving average price for the stock is $ 8.71 and the 200-day moving average price is $ 6.60.

In other news, CEO Helen Sabzevari sold 9,040 shares in the company in a transaction on Tuesday, January 5th. The stock sold at an average price of $ 10.56 for a total value of $ 95,462.40. Upon completion of the transaction, the chief executive officer now directly owns 424,299 shares in the company valued at $ 4,480,597.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In addition, SVP Jeffrey Thomas Perez sold 9,382 shares of the company in a transaction on Wednesday December 16. The shares were sold at an average price of $ 7.20 for a total value of $ 67,550.40. Upon completion of the transaction, the senior vice president now holds 268,229 shares in the company valued at $ 1,931,248.80. The disclosure for this sale can be found here. In the past ninety days, insiders have sold 64,850 shares in the company, valued at $ 580,696. 50.70% of the shares are currently owned by insiders. (adsbygoogle = window.adsbygoogle || []). push ({});

Hedge funds and other institutional investors recently changed their positions in the business. Morgan Stanley acquired a new stake in Precigen for approximately $ 2,245,000 in the first quarter. Cambridge Investment Research Advisors Inc. increased its stake in Precigen by 6.0% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 74,582 shares in the biotechnology company, valued at $ 261,000, after purchasing an additional 4,225 shares last quarter. DekaBank Deutsche Girozentrale bought a new position in Precigen worth around USD 170,000 in the third quarter. Daiwa Securities Group Inc. increased its stake in Precigen by 90.9% in the third quarter. Daiwa Securities Group Inc. now owns 97,218 shares in the biotechnology company, valued at $ 340,000, after purchasing an additional 46,300 shares last quarter. Eventually, Verus Financial Partners Inc. bought a new position in Precigen for approximately $ 36,000 in the third quarter. Hedge funds and other institutional investors own 66.57% of the company’s shares.

Precigen, Inc discovers and develops the next generation of gene and cell therapies in the United States. It also offers disease-modifying therapeutics; genetically modified pigs for regenerative medicine applications; proprietary methane bioconversion platform that converts natural gas into energy and chemical products; as well as reproductive and embryo transfer technologies.

This instant messaging alert was generated using narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate coverage possible. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send any questions or comments about this story to [email protected]

Now that the Biden administration has full responsibility, student debt relief has come to the fore. Look at these numbers. Student debt is estimated at $ 1.7 trillion. The average student has about $ 30,000 in student loans.

If $ 10,000 student debt were canceled, it is estimated that a third of borrowers (between 15 million and 16.3 million) would become debt free. Of course, when the number hits $ 50,000, as some lawmakers suggest, the impact would be even greater.

Setting aside personal thoughts about the wisdom to pursue this path can be a major boost to the economy.

And as an investor, it’s fair to ask where the money would go. After all, it doesn’t hurt if investors also benefit from this incentive.

One counter-argument is that the lack of a monthly payment may not provide enough cash to make an impact. Senator Elizabeth Warren, however, pointed to the effect that student loans have in preventing many of the Millennial and Gen Z generations from pursuing big life goals like buying a home, starting a business, or starting a family.

With that in mind, we’ve put together this particular presentation that will highlight 7 stocks that are likely to benefit from getting rid of the burden of student loans for borrowers.

Fill out the form below to receive the latest headlines and analyst recommendations for your stocks with our free daily email newsletter:

Sign up to MarketBeat All Access to access the full Get Research From MarketBeat:

View the latest news, buy / sell ratings, SEC filings, and insider deals for your stocks. Compare your portfolio performance against leading indices and get personalized stock ideas based on your portfolio.

Get stock ideas daily with the best Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. See what stocks are up to date on social media with MarketBeat’s Trending Stock Report.

Identify stocks that match your criteria with seven unique stock screeners. See what’s happening in the market with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access Stock Screener, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Would you like to see which stocks are moving? View our full range of financial calendars and market data tables for free.

Receive free world class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat enables individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, company buybacks, dividends, earnings, business reports, financial data, insider trading, IPOs, SEC filings, or stock splits, MarketBeat has the objective information you need to analyze stocks. Learn more.

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St # 105, Sioux Falls, SD 57103 | [Email protected] | (844) 978-6257
MarketBeat does not provide financial advice or make recommendations or offers to buy stocks or sell any securities. Learn more.
Don’t sell my information

© 2021 The market data provided will be delayed by at least 10 minutes and hosted by Barchart Solutions. The information is provided « as is » and for informational purposes only, not for commercial or advisory purposes, and is delayed. Please see the disclaimer for all delays and terms of use for exchanges. Basic company data from Zacks Investment Research. As a bonus for subscribing to our e-mail newsletters, you will also receive a free subscription to the Liberty Through Wealth e-newsletter. You can unsubscribe at any time.

Enter your email address below to receive a quick daily summary of upgrades, downgrades and new coverage from Analysts with’s FREE daily email newsletter.